bronchoscopi
bronchoalveolar
lavag
bal
import
diagnost
tool
evalu
ahsct
recipi
new
pulmonari
infiltr
without
clinic
respons
empir
therapi
util
depend
cultur
molecular
diagnost
result
capabl
chang
medic
manag
studi
prior
avail
polymeras
chain
reaction
pcr
antibiot
withdrawn
ahsct
recipi
studi
aim
determin
aspergillu
galactomannan
antigen
aga
multiplex
pcr
ad
tradit
bal
test
affect
antimicrobi
treatment
ahsct
recipi
new
pulmonari
infiltr
first
bal
complet
ahsct
patient
age
januari
juli
author
institut
includ
decis
perform
bal
discret
attend
physician
care
patient
bal
fluid
submit
gram
stain
bacteri
mycobacteri
fungal
cultur
multiplex
pcr
aga
cytopatholog
studi
approv
virginia
commonwealth
univers
institut
review
board
posit
bal
defin
posit
cultur
multiplex
pcr
elev
aga
optic
densiti
od
andor
cytolog
includ
detect
pneumocysti
jirovecii
posit
bacteri
cultur
requir
speci
isol
exclud
coagulaseneg
staphylococcu
mix
respiratori
flora
posit
fungal
cultur
requir
presenc
fungal
coloni
except
noncryptococcu
yeast
multiplex
pcr
use
commerci
kit
biofir
detect
adenoviru
coronaviru
human
metapneumoviru
human
rhinovirusenteroviru
influenza
influenza
b
parainfluenza
subtyp
respiratori
syncyti
viru
rsv
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
diffus
alveolar
hemorrhag
dah
diagnos
per
guidelin
chang
manag
defin
escal
deescal
antibiot
antifung
antivir
adapt
antifung
initi
prednison
within
day
bal
sinc
time
interv
obtain
aga
result
author
institut
deescal
defin
cessat
one
multipl
agent
convers
oral
therapi
transit
narrow
spectrum
escal
defin
ad
new
antimicrobi
agent
transit
broader
spectrum
fungal
adapt
transit
altern
agent
within
class
antifung
antimicrobi
use
within
day
bal
consid
prior
therapi
ahsct
perform
bone
marrow
transplant
unit
author
institut
condit
regimen
immunosuppress
support
therapi
follow
intern
accept
protocol
levofloxacin
fluconazol
use
antiinfect
prophylaxi
prophylaxi
cytomegaloviru
cmv
pneumocysti
jirovecii
pneumonia
use
accord
guidelin
descript
analysi
perform
use
median
interquartil
rang
iqr
continu
variabl
due
nonnorm
distribut
frequenc
percentag
categor
variabl
use
fisher
exact
test
compar
categor
variabl
anova
continu
variabl
pvalu
less
consid
statist
signific
analysi
perform
use
jmp
pro
sa
institut
cari
nc
usa
bal
perform
ahsct
recipi
studi
period
procedur
exclud
patient
age
subsequ
procedur
patient
bal
perform
transplant
patient
bal
ahsct
includ
patient
demograph
antimicrobi
bronchoscopi
bal
result
describ
tabl
antimicrobi
therapi
start
within
two
day
day
bal
eleven
patient
receiv
antimicrobi
bal
posit
infecti
etiolog
mostli
elev
aga
follow
multiplex
pcr
posit
bacteri
fungal
afb
cultur
none
patient
posit
bacteri
cultur
levofloxacin
prophylaxi
patient
posit
fungal
result
antifung
prophylaxi
patient
posit
bal
aga
also
posit
serum
aga
posit
multiplex
pcr
virus
nine
patient
multipl
infecti
etiolog
posit
multiplex
pcr
twentyeight
patient
concomit
nonpulmonari
infect
patient
found
pneumocysti
jirovecicii
legionella
cryptococcu
cytolog
antigen
test
antimicrobi
adjust
patient
tabl
ii
overal
antibiot
escal
occur
associ
posit
bal
bacteri
cultur
tabl
ii
antibiot
deescal
like
elev
aga
tabl
ii
antivir
initi
like
posit
bal
multiplex
pcr
tabl
ii
antifung
like
escal
chang
elev
aga
tabl
ii
patient
neg
bal
like
start
steroid
bal
help
determin
etiolog
pulmonari
complic
optim
antimicrobi
includ
escal
antibiot
target
organ
isol
believ
chang
practic
bal
valuabl
result
posit
aggreg
neg
bal
work
offer
assur
provid
address
noninfecti
etiolog
critic
intens
care
set
antiinflammatori
therapi
high
dose
steroid
tumor
necrosi
factor
inhibitor
tcell
deplet
agent
consid
pulmonari
graft
versu
host
diseas
suspect
superimpos
infect
patient
requir
initi
target
therapi
microorgan
isol
bacteri
cultur
previous
cover
includ
virul
organ
nocardia
nova
complex
pseudomona
aeruginosa
haemophili
influenza
stentrophomona
maltophilia
antibiot
also
escal
due
sever
ill
despit
neg
cultur
data
cover
altern
infect
endocard
like
use
antimicrobi
prophylaxi
effect
limit
bacteri
infect
due
suscept
organ
may
ad
select
resist
bacteria
stenotrophomona
nocardia
spp
bal
critic
recogn
treat
invas
fungal
infect
prompt
antifung
escal
initi
target
treatment
isol
rhizomucor
spp
two
patient
elev
bal
aga
also
elev
serum
aga
bal
assist
diagnosi
infect
find
import
delay
treatment
carri
potenti
increas
mortal
recogn
american
thorac
societi
guidelin
suggest
move
bal
aga
request
bal
aspergillu
pcr
serum
aga
neg
cutoff
serum
aga
sensit
approxim
cutoff
sensit
reduc
specif
increas
bal
aga
cutoff
sensit
specif
increas
respect
addit
aspergillu
spp
account
invas
fungal
infect
ahsct
remain
includ
deadli
pathogen
includ
zygomycet
fusarium
usa
dematiac
rare
mold
may
requir
cultur
tissu
biopsi
diagnosi
endem
mycos
account
invas
fungal
infect
ahsct
may
amen
serolog
antigen
test
without
invas
procedur
posit
multiplex
pcr
associ
antivir
initi
ribavirin
parainfluenza
peramivir
influenza
tabl
ii
howev
result
similar
nasopharyng
bal
multiplex
pcr
note
prior
studi
unclear
multiplex
pcr
test
adequ
diagnos
lrti
studi
need
done
evalu
bal
remain
necessari
detect
coinfect
patient
posit
multiplex
pcr
also
posit
bacteri
cultur
elev
aga
tabl
report
viral
bacteri
coinfect
particularli
adenoviru
rhinoviru
associ
higher
morbiditymort
understand
limit
would
interest
investig
larger
studi
effect
viral
ill
bacteri
fungal
coinfect
affect
treatment
outcom
determin
aggress
prophylaxi
diagnost
test
would
benefit
patient
bal
also
major
role
antimicrobi
deescal
antibiot
either
stop
convert
oral
patient
neg
bal
bacteri
cultur
elev
aga
predict
antibiot
deescal
tabl
ii
highlight
new
role
bal
antibiot
optim
neg
bal
associ
initi
steroid
treatment
condit
includ
graft
versu
host
diseas
pneumon
dah
complic
engraft
tabl
ii
even
though
bal
aid
diagnosi
except
dah
mitig
risk
start
steroid
lower
suspicion
pulmonari
infect
studi
limit
includ
potenti
select
bia
patient
bal
includ
fact
result
singl
hospit
bal
perform
discret
attend
physician
therefor
patient
group
includ
deem
elig
procedur
like
urg
clinic
statu
control
group
comparison
without
avail
sputum
cultur
nasal
multiplex
respiratori
pathogen
panel
serum
aga
fungal
urin
antigen
test
would
like
bias
includ
deem
less
sick
well
consid
high
risk
elig
bronchoscopi
due
high
oxygen
requir
bleed
risk
would
uneth
randomli
assign
patient
bronchoalveolar
lavag
due
known
risk
benefit
addit
studi
across
multipl
hospit
would
valuabl
confirm
result
multivari
regress
analysi
could
perform
due
low
sampl
size
summari
studi
found
bal
benefici
diagnost
tool
evalu
new
pulmonari
infiltr
ahsct
recipi
bal
permit
target
antimicrobi
treatment
posit
affect
antimicrobi
deescal
guid
manag
noninfecti
diagnost
consider
data
inform
local
antimicrobi
stewardship
effort
addit
studi
need
confirm
find
identifi
bal
use
improv
antimicrobi
prescrib
author
declar
conflict
interest
financi
disclosur
